1. Home
  2. KBH vs SRRK Comparison

KBH vs SRRK Comparison

Compare KBH & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KB Home

KBH

KB Home

HOLD

Current Price

$54.08

Market Cap

3.8B

ML Signal

HOLD

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$40.30

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBH
SRRK
Founded
1957
2012
Country
United States
United States
Employees
N/A
289
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.6B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
KBH
SRRK
Price
$54.08
$40.30
Analyst Decision
Hold
Strong Buy
Analyst Count
12
11
Target Price
$61.70
$55.10
AVG Volume (30 Days)
764.0K
1.1M
Earning Date
03-19-2026
05-28-2026
Dividend Yield
1.89%
N/A
EPS Growth
N/A
N/A
EPS
6.15
N/A
Revenue
$4,547,002,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.30
$449.79
P/E Ratio
$8.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$49.70
$22.71
52 Week High
$68.71
$49.82

Technical Indicators

Market Signals
Indicator
KBH
SRRK
Relative Strength Index (RSI) 29.89 34.35
Support Level $50.16 $29.32
Resistance Level $56.50 $42.54
Average True Range (ATR) 1.66 2.27
MACD -1.01 -0.67
Stochastic Oscillator 11.01 7.79

Price Performance

Historical Comparison
KBH
SRRK

About KBH KB Home

KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

Share on Social Networks: